Gapping up
In reaction to strong earnings/guidance: ENTA +2.6%.
M&A news: GA +10.5% (receives proposal from the co's Chairman to acquire the company at $11.75 per share).
Select EU financial related names showing strength: NBG +1.7%, DB +1.5%, UBS +1.4%, LYG +1%, RBS +0.7%.
Select 3-D printing names showing strength: VJET +5%, ONVO +4.9%, DDD +1.4%.
Dialysis stocks gapping up on CMS payment rate changes for end-stage renal disease facilities in 2014: FMS +7.3%, DVA +3.9%, NXTM +3.6%.
Other news: OREX +19.7% (successful results of the interim analysis of the Light Study; co will resubmit the Contrave NDA in the next few weeks), ARIA +8.7% (cont strength), GLUU +6.9% (attributed to positive blog mention making the rounds), SIRI +4.9% (positive Barron's mention), JNY +4% (Sycamore in discussions to purchase JNY for $16/share, according to reports), CYCC +3.7% (announces data safety monitoring board recommendation to continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML), ANIK +3% (to join S&P SmallCap 600), STML +2.9% (presents results of clinical trial results with a synthetic peptide vaccine for brain cancer), DAL +2.1% (still checking), YGE +2% (to supply 15 MW PV modules to Solarcentury in the UK), BBY +1.9% (ticking higher on light volume by 2% following positive mention on MadMoney), RPRX +1.2% (reports it has been granted a face to face meeting with the FDA to discuss the pivotal Androxal efficacy studies), KTOS +1% (discontinues proposed refinancing effort), YHOO +0.9% (in negotiations with Katie Couric, according to reports), ARWR +0.8% (submits application to begin Phase 2a trial of ARC-520 for the treatment of chronic hepatitis B infection).
Analyst comments: DVAX +6.2% (upgraded to Buy at MLV & Co), AA +3.8% (upgraded to Buy at Goldman), MDAS +3.5% (upgraded to Buy from Hold at KeyBanc Capital Mkts), EGHT +2.8% (initiated with Buy at Deutsche Bank, initiated with Overweight at Barclays, initiated with a Buy at BofA/Merrill), PAGP +2.7% (initiated with a Overweight at JP Morgan), CAT +1.7% (upgraded to Buy at BofA/Merrill), SYK +1.6% (upgraded to Outperform from Mkt Perform at Bernstein), UN +1.5% (upgraded to Outperform from Neutral at Exane BNP Paribas), KCG +1.2% (upgraded to Outperform from Mkt Perform at Raymond James), ATVI +1.1% (added to to Stifel Select List).